Theravance Biopharma (TBPH) EBIAT (2016 - 2025)
Historic EBIAT for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $3.6 million.
- Theravance Biopharma's EBIAT rose 12846.91% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.3 million, marking a year-over-year increase of 15939.96%. This contributed to the annual value of -$56.4 million for FY2024, which is 221.95% down from last year.
- As of Q3 2025, Theravance Biopharma's EBIAT stood at $3.6 million, which was up 12846.91% from $54.8 million recorded in Q2 2025.
- In the past 5 years, Theravance Biopharma's EBIAT registered a high of $916.6 million during Q3 2022, and its lowest value of -$86.5 million during Q1 2021.
- Its 5-year average for EBIAT is $26.4 million, with a median of -$15.5 million in 2024.
- Its EBIAT has fluctuated over the past 5 years, first soared by 173947.59% in 2022, then tumbled by 10097.64% in 2023.
- Over the past 5 years, Theravance Biopharma's EBIAT (Quarter) stood at -$57.8 million in 2021, then skyrocketed by 75.34% to -$14.3 million in 2022, then surged by 40.31% to -$8.5 million in 2023, then crashed by 82.46% to -$15.5 million in 2024, then skyrocketed by 123.28% to $3.6 million in 2025.
- Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.6 million during Q1 2025.